A Combined Investigation of the Protective Impact of the NOF/Q Antagonist LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 29 Jan 2025 New trial record